Highest-materiality recent filing
Gilead Q2 2026 Revenue Up 10% to $7.8B; Diluted Loss Per Share $(8.45) on $11.2B IPR&D Charges
Total Q2 2026 revenues increased 10% to $7.8 billion compared to Q2 2025.
Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges
Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).
Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma
Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.
Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B
$115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.
Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B
Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.
Gilead Sciences EVP & General Counsel Deborah Telman to depart Dec 5, 2025
Deborah H. Telman will step down as EVP, Corporate Affairs and General Counsel effective December 5, 2025.
GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.
Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036
Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.
Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised
Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).
Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance
Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.
Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment
Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.
Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025
Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.
Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance
GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.
Gilead Q2 revenue $7.0B (+5%), Non-GAAP EPS $2.01; raised Non-GAAP FY guidance to $3.60-$3.90
Q2 2024 revenue $7.0B (+5% YoY); GAAP diluted EPS $1.29 (prior $0.83), Non-GAAP diluted EPS $2.01 (prior $1.34).
Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed
GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.
Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline
Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.
Gilead to acquire CymaBay for $4.3B, adding seladelpar for PBC with FDA priority review
Gilead to pay $32.50/share in cash, total equity value of $4.3 billion, a 27% premium over CymaBay's Feb 9 close.
Gilead Q4 revenue $7.1B (-4% YoY); FY23 non-GAAP EPS $6.72; guides FY24 product sales $27.1-27.5B
Q4 2023 GAAP EPS $1.14 (down from $1.30); non-GAAP EPS $1.72 (up from $1.67).
Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance
Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.
Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC
ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.
Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury
Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.
Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15
Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.
Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.
Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance
Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.
Gilead settles patent litigation for Descovy, Vemlidy, Odefsey; generic licenses begin 2031-2032
Agreements with Lupin, Apotex, Macleods, Hetero, Cipla resolve patent challenges for HIV drugs.
Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance
Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).
Gilead Q1 revenue $6.6B (+3%), non-GAAP EPS $2.12 (+4%), GAAP EPS $0.02 due to $2.7B impairment
GAAP diluted EPS $0.02 vs $1.37 Q1 2021 due to $2.7B IPR&D impairment; non-GAAP EPS $2.12, +4% YoY.
Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer
TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.
Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B
GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)
Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027
One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.
GAAP diluted EPS $2.05 vs $0.29 YoY; non-GAAP diluted EPS $2.65 vs $2.11 YoY.
Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance
Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).
The Company’s Board of Directors has appointed Diane E. Wilfong as the Company’s interim Corporate Controller and Chief Accounting Officer, and designated her as the interim principal accounting officer, effective immediately.
Sandra Patterson, the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer and the Company’s principal accounting officer, has decided to leave the Company.
announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company.
On March 10, 2024, Kevin E. Lofton notified the Board of Directors (the “Board”) of Gilead Sciences, Inc., a Delaware corporation (the “Company”), of his decision to retire from the Board, effective as of the conclusion of his term at the Company’s next annual meeting of stockholders to be held on May 8, 2024.
the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting.
announced that Diane Wilfong plans to step down from her positions as the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer effective March 1, 2023
The Company has named Sandra Patterson, who currently serves as Vice President, Assistant Controller, to be the Company’s Senior Vice President, Corporate Controller, and principal accounting officer, effective March 1, 2023
In connection with the previously announced plans for Brett A. Pletcher to retire as the Company’s Executive Vice President, Corporate Affairs and General Counsel, the Compensation and Talent Committee of the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the “Company”), on May 25, 2022, approved compensation terms for Mr. Pletcher to serve in a part-time capacity following such retirement
On January 6, 2022, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Brett A. Pletcher plans to retire from his position as the Company’s Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary.
Max materiality 1.00 · Median 0.75 · Most common event earnings